A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multiple-dose Study in Healthy Subjects and Chronic Hepatitis B Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Freethiadine
Latest Information Update: 08 Aug 2023
At a glance
- Drugs Freethiadine (Primary) ; Entecavir
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Sunshine Lake Pharma
Most Recent Events
- 24 Jun 2023 Results assessing safety, tolerability, pharmacokinetics (PK), and 28-dayantiviral activity of freethiadine in two randomized, double-blinded phase I studies in healthy subjects and patients with chronic HBV infection presented at the European Association for the Study of the Liver Congress 2023
- 11 Apr 2023 Status changed from recruiting to completed.
- 31 May 2022 New trial record